Precision Medicine in Epilepsy: Diagnostic Yield by Next-Generation Sequencing and Genotype–Phenotype Findings in a Romanian Cohort
4 affiliations
- 1Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
- 2Regional Center for Medical Genetics Iasi, Saint Mary’s Emergency Children Hospital, 700309 Iasi, Romania
- 3Iuliu Haţieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
- 4Neurology, Saint Mary’s Emergency Children Hospital, 700309 Iasi, Romania
Abstract
Epilepsy ranks among the most prevalent neurological disorders globally, with a substantial proportion of cases, particularly in pediatric populations, attributed to genetic etiologies. This study provides the first molecular characterization of suspected genetic epilepsy in a pediatric cohort from the Moldova region of Romania. Following the exclusion of 124 patients with secondary acquired or structural causes from an initial cohort of 159, we enrolled 35 individuals with a high suspicion of primary genetic epilepsy, who underwent targeted gene panel testing or whole-exome sequencing (WES). Pathogenic (P) or likely pathogenic (LP) variants were identified in 13 patients (37.1%); variants of uncertain significance (VUSs) were identified in another 13 patients (37.1%), comprising 15 distinct VUSs; and negative results were observed in the remaining 9 patients (25.7%). Genes regulating ion channels and synaptic signaling, notably SCN1A, KCNB1, and GNAO1, were predominantly implicated in early-onset, drug-resistant epileptic encephalopathies, whereas structural copy number variations (CNVs) underpinned syndromic phenotypes. We identified one novel pathogenic variant in SCN1A, thereby expanding the known mutational spectrum. Furthermore, in silico predictions and de novo occurrence patterns supported the pathogenicity of several VUSs, underscoring the critical value of familial segregation analyses. Despite the notable diagnostic yield, the high VUS rate underscores the ongoing need for refined variant interpretation criteria and the integration of functional validation data to improve classification accuracy. Collectively, our findings support the clinical utility of next-generation sequencing (NGS) in informing therapeutic decisions, enabling genetic counseling, and improving prognostic accuracy. These results suggest that NGS should be considered early in the diagnostic workup of unexplained or drug-resistant epilepsy, particularly in patients with clinical features suggestive of a genetic etiology.
Related
- Quantifying the diagnostic time gap in precision oncology: A retrospective analysis of potential time savings from same-day cartridge-based molecular testing versus next-generation sequencing in cytology specimens
- Diagnostic Yield and Clinical Phenotype in a Lithuanian Familial Hypercholesterolemia Cohort with Heterogeneous Sequencing Platforms
- Diagnostic Approach to Genetic Obesity in Children: From Pathophysiology to Precision Medicine-A Narrative Review.
- Precision Orthobiologics for Chronic Musculoskeletal Pain: Matching Biology, Pathology, and Patient Phenotype-A Narrative Review of Current Evidence and Future Directions in Regenerative Pain Medicine.
- Mycobacterium mageritense submandibular lymphadenitis in children: diagnostic challenges and the role of metagenomic next-generation sequencing: two case reports and literature review.
BibTeX
@article{butnariu2026precision,
title = {{Precision Medicine in Epilepsy: Diagnostic Yield by Next-Generation Sequencing and Genotype–Phenotype Findings in a Romanian Cohort}},
author = {Lăcrămioara Ionela Butnariu and Ecaterina Grigore and Thomas Gabriel Schreiner and Aurora Băgiag and Setalia Popa and Ioana Grigore},
journal = {International journal of molecular sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27198878},
url = {https://europepmc.org/article/PMC/PMC13665156},
note = {CC BY},
}
RIS
TY - JOUR
TI - Precision Medicine in Epilepsy: Diagnostic Yield by Next-Generation Sequencing and Genotype–Phenotype Findings in a Romanian Cohort
AU - Lăcrămioara Ionela Butnariu
AU - Ecaterina Grigore
AU - Thomas Gabriel Schreiner
AU - Aurora Băgiag
AU - Setalia Popa
AU - Ioana Grigore
PY - 2026
DA - 2026/10/01
JO - International journal of molecular sciences
DO - 10.3390/ijms27198878
UR - https://europepmc.org/article/PMC/PMC13665156
AB - Epilepsy ranks among the most prevalent neurological disorders globally, with a substantial proportion of cases, particularly in pediatric populations, attributed to genetic etiologies. This study provides the first molecular characterization of suspected genetic epilepsy in a pediatric cohort from the Moldova region of Romania. Following the exclusion of 124 patients with secondary acquired or structural causes from an initial cohort of 159, we enrolled 35 individuals with a high suspicion of primary genetic epilepsy, who underwent targeted gene panel testing or whole-exome sequencing (WES). Pathogenic (P) or likely pathogenic (LP) variants were identified in 13 patients (37.1%); variants of uncertain significance (VUSs) were identified in another 13 patients (37.1%), comprising 15 distinct VUSs; and negative results were observed in the remaining 9 patients (25.7%). Genes regulating ion channels and synaptic signaling, notably SCN1A, KCNB1, and GNAO1, were predominantly implicated in early-onset, drug-resistant epileptic encephalopathies, whereas structural copy number variations (CNVs) underpinned syndromic phenotypes. We identified one novel pathogenic variant in SCN1A, thereby expanding the known mutational spectrum. Furthermore, in silico predictions and de novo occurrence patterns supported the pathogenicity of several VUSs, underscoring the critical value of familial segregation analyses. Despite the notable diagnostic yield, the high VUS rate underscores the ongoing need for refined variant interpretation criteria and the integration of functional validation data to improve classification accuracy. Collectively, our findings support the clinical utility of next-generation sequencing (NGS) in informing therapeutic decisions, enabling genetic counseling, and improving prognostic accuracy. These results suggest that NGS should be considered early in the diagnostic workup of unexplained or drug-resistant epilepsy, particularly in patients with clinical features suggestive of a genetic etiology.
SN - 1422-0067
ER -